# Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia

> **NCT04082286** · PHASE1 · COMPLETED · sponsor: **Great Ormond Street Hospital for Children NHS Foundation Trust** · enrollment: 9 (actual)

## Conditions studied

- Acute Myeloblastic Leukemia
- Acute Lymphoblastic Leukemia
- Juvenile Myelomonocytic Leukemia

## Interventions

- **OTHER:** Yttrium-90 labelled monoclonal antibody against CD66

## Key facts

- **NCT ID:** NCT04082286
- **Lead sponsor:** Great Ormond Street Hospital for Children NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2020-05-14
- **Final completion:** 2020-05-14
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04082286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04082286, "Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04082286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*